<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR90">
 <label>90.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Lundberg</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Brahms</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Hooper</surname>
    <given-names>I</given-names>
   </name>
   <name>
    <surname>Carey</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Lin</surname>
    <given-names>S-C</given-names>
   </name>
   <name>
    <surname>Dahal</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Narayanan</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Kehn-Hall</surname>
    <given-names>K</given-names>
   </name>
  </person-group>
  <article-title>Repurposed FDA-Approved drug sorafenib reduces replication of Venezuelan equine encephalitis virus and other alphaviruses</article-title>
  <source>Antivir Res</source>
  <year>2018</year>
  <volume>157</volume>
  <fpage>57</fpage>
  <lpage>67</lpage>
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2018.07.005</pub-id>
  <?supplied-pmid 29981794?>
  <pub-id pub-id-type="pmid">29981794</pub-id>
 </element-citation>
</ref>
